Health Care·Pharmaceuticals·$4.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.59 | N/A | +130.00% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $2.59 | N/A | +130.00% |
| Revenue | N/A | N/A | N/A |
Tone: Confident
Management expressed confidence in their operational performance despite not providing specific revenue figures. They emphasized their commitment to growth through strategic partnerships.
We are pleased with our strong EPS performance this quarter.
Our focus remains on driving growth through our partnerships.
Ligand Pharmaceuticals reported a strong earnings per share, significantly exceeding expectations, which contributed to a modest increase in stock price. The lack of revenue data leaves some uncertainty, but management's positive outlook suggests they are on a solid path. Investors may view the EPS beat as a sign of operational strength, despite the absence of detailed revenue figures.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
KRAFT HEINZ CO
Aug 3, 2018